"id","uuid:ID","versionIdentifier","rationale","instanceType"
"StudyVersion_1","47e48338-e920-4e05-8038-fbf33d116a96","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion"
